

## Supplementary

Stage	Definition
<b>T1</b>	Tumor < 3 cm in greatest diameter, confined to midline vermis, roof of the fourth ventricle, or cerebellar hemisphere.
<b>T2</b>	Tumor ≥ 3 cm and/or extending into one adjacent structure (e.g., floor of fourth ventricle, foramen of Luschka, or cerebellar peduncle).
<b>T3a</b>	Tumor infiltrating the midbrain.
<b>T3b</b>	Tumor invading the medulla oblongata or cervical spinal cord.
<b>T4</b>	Tumor extending into the aqueduct of Sylvius or upper cervical canal.
<b>M0</b>	No evidence of metastasis.
<b>M1</b>	Tumor cells present in cerebrospinal fluid.
<b>M2</b>	Gross nodular seeding in cerebellum, cerebral subarachnoid space, or in the third/lateral ventricles.
<b>M3</b>	Gross nodular seeding in spinal subarachnoid space.
<b>M4</b>	Extraneural metastases.

Figure S1. Chang Staging System for medulloblastoma

Response	Definition
----------	------------

<b>Category</b>	
<b>Complete Response (CR)</b>	Disappearance of all target lesions on MRI; no new lesions; no clinical evidence of disease; off corticosteroids (or on physiologic replacement doses only).
<b>Partial Response (PR)</b>	$\geq 50\%$ decrease in the sum of the products of perpendicular diameters (SPD) of target lesions compared to baseline; no new lesions; stable/improved clinical status; stable/decreasing corticosteroids.
<b>Minor Response (MR)</b>	25–49% decrease in SPD of target lesions compared to baseline; no new lesions; stable/improved clinical status; stable/decreasing corticosteroids.
<b>Stable Disease (SD)</b>	$< 25\%$ decrease or $< 25\%$ increase in SPD compared to baseline; no new lesions; stable clinical status.
<b>Progressive Disease (PD)</b>	$\geq 25\%$ increase in SPD of target lesions compared to smallest recorded value (nadir) or appearance of new lesions; or clear clinical deterioration not attributable to other causes.

Figure S2. RAPNO Criteria for medulloblastoma Response Assessment

All medulloblastoma patients	N=29
Radiotherapy	29 (100%)
CSI	
No	1 (3.5%)
Yes	27 (93.0%)
Unclear (therapy performed at other Center)	1 (3.5%)
Focal boost	
No	3 (10.3%)
Yes	22 (75.9%)
Unclear (therapy performed at other Center)	4 (3.8%)
Total dose, Gy	53.6 (53.6-53.6)
Chemotherapy	
Cisplatin-etoposide±cyclophosphamide	18 (62.1%)
Cisplatin-lomustine±vincristine	6 (20.7%)
HIT SKK protocol	2 (6.9%)
PNET5 protocol	1 (3.5%)
None (due to comorbidities)	2 (6.9%)
Median number of cycles	4 (3-8)
Radiological response at first-line treatment	
CR	19 (65.5%)
PR	5 (17.2%)
SD	1 (3.5%)
PD	0 (0%)
Not available	4 (13.8%)

CSI: craniospinal irradiation; Gy: Gray; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease